Gareth King
Life Science Partner @ GM&C Life Sciences Fund
Manchester, United Kingdom
Gareth King is a seed investor at GM&C Life Sciences Fund in Manchester focused on Health Care and Medical Device. Gareth is a Life Science Partner with Catapult’s GM&C Life Sciences Fund, where he has been leading and managing investments since the Fund launched in late 2015.Gareth was most recently CEO of Critical Pharmaceuticals, a clinical stage biotechnology company utilising a proprietary drug delivery technology to develop a pipeline of uniquebiological drug products, which raised >£4m from investors including Catapult Ventures and the Welcome Trust. Gareth was previously VP Business Development at Pharmaceutical Profiles, which he joined from Manchester-based start-up Cyprotex, where he was Commercial Director.Gareth began his career in Boston, USA as a Research Fellow at Harvard Medical School. He moved back to the UK and was based at Alderley Park for over 3 years as Bioinformatics Project Manager with AstraZeneca, before joining California-based genomics company Incyte.Gareth holds an BSc in Microbiology from Sheffield University and a PhD in Molecular Genetics from Edinburgh University.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Gareth King invests in
Stages Gareth King invests in
Countries Gareth King invests in
Investment Focus
Industry
- Health Care 2 (100%)
- Medical Device 2 (100%)
- Medical 1 (50%)
- Life Science 1 (50%)
- Pharmaceutical 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Renephra
|
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal. We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas. This is a substantial patient group with unmet clinicalneeds and is an estimated £1billion market worldwide. Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability. | $302K / Seed / Mar 27, 2018 | |
SwabTech
|
SwabTech Ltd is a UK registered medical device company that has spun out of the UK NHS to develop, evaluate and commercialise an automatic swab washing device to support the use of Intra-Operative Cell Salvage within operating theatres.SwabTech are developing an automated Surgical Swab Washer to enhance blood recovery and reuse during high bloodloss surgical procedures. SwabTech's patented Surgical Swab-Washer automates a process currently performed by hand, recovering blood from swabs used in the hospital operating theatre. This blood can then be processed and transfused back into the patient, an established procedure used in a wide range of operations associated with high blood loss, and is known to be a cost-effective means to improve clinical outcomes. | $759K / Seed / Sep 29, 2016 |
Co-Investors
About GM&C Life Sciences Fund
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
GM&C Life Sciences Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Whitcombe
Venture Partner
|
|||
David Whitcombe
Venture Partner
|
|||
Chris Spencer
Venture Partner
|
|||
|
Gareth King
Life Science Partner
|
|||
Kevin D'Silva
Venture Partner - Medical Devices
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Gareth King invest in?
Gareth King invests primarily in Health Care, Medical Device and Medical startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Gareth King last invest?
The most recent investment recorded for Gareth King closed in Mar 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
